| scholarly article | Q13442814 |
| P2093 | author name string | Craig H Selzman | |
| Matthew Rondina | |||
| Stephen H McKellar | |||
| Antigone Koliopoulou | |||
| P2860 | cites work | Clinical significance of PlA polymorphism of platelet GP IIb/IIIa receptors during long-term VAD support | Q28167511 |
| Extensive coagulation monitoring in patients after implantation of the MicroMed Debakey continuous flow axial pump | Q28171252 | ||
| Platelet activation and aggregation profile in prolonged external ventricular support | Q28209924 | ||
| Megakaryocytes and beyond: the birth of platelets | Q34215516 | ||
| Membrane microparticles: two sides of the coin | Q34384910 | ||
| Platelets and von Willebrand factor | Q35119428 | ||
| Shear-induced platelet receptor shedding by non-physiological high shear stress with short exposure time: glycoprotein Ibα and glycoprotein VI. | Q35181401 | ||
| Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients? | Q35211180 | ||
| Systemic Inflammatory Response Syndrome After Contentious-Flow Left Ventricular Assist Device Implantation and Change in Platelet Mitochondrial Membrane Potential | Q35842168 | ||
| Mechanisms of thrombopoiesis | Q36230854 | ||
| Activation and shedding of platelet glycoprotein IIb/IIIa under non-physiological shear stress | Q36608114 | ||
| Platelet glycoprotein Ibα ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices. | Q37625884 | ||
| Science for surgeons: understanding pump thrombogenesis in continuous-flow left ventricular assist devices | Q38298145 | ||
| Emerging evidence for platelets as immune and inflammatory effector cells | Q38310270 | ||
| Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation | Q38471078 | ||
| Seventh INTERMACS annual report: 15,000 patients and counting | Q40371643 | ||
| Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study. | Q40413584 | ||
| Platelet activation markers in patients with heart assist device | Q40435913 | ||
| The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies. | Q41244835 | ||
| On the trail of microparticles | Q42877173 | ||
| Acquired von Willebrand Syndrome in Patients With an Axial Flow Left Ventricular Assist Device | Q42925731 | ||
| Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage. | Q43488174 | ||
| Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices | Q44292696 | ||
| Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen | Q44929986 | ||
| Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). | Q45982333 | ||
| Evaluation of platelet activation in patients supported by the Jarvik 2000* high-rotational speed impeller ventricular assist device | Q46101998 | ||
| Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. | Q46360793 | ||
| Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device | Q46430418 | ||
| Unexpected abrupt increase in left ventricular assist device thrombosis | Q46819259 | ||
| Intraplatelet reactive oxygen species, mitochondrial damage and platelet apoptosis augment non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist device. | Q46846191 | ||
| Local glycoprotein IIb/IIIa receptor inhibitor delivery from the pump surface attenuates platelet adhesion in continuous flow ventricular assist devices | Q47268937 | ||
| Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. | Q47821942 | ||
| Advanced heart failure treated with continuous-flow left ventricular assist device | Q48952442 | ||
| The effect of surface roughness on activation of the coagulation system and platelet adhesion in rotary blood pumps. | Q51015047 | ||
| Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. | Q51068100 | ||
| Acquired von Willebrand Syndrome in Continuous-Flow Ventricular Assist Device Recipients | Q51750814 | ||
| Platelet damage caused by the centrifugal pump: in vitro evaluation by measuring the release of alpha-granule packing proteins. | Q52255226 | ||
| Gold standard in anticoagulation assessment of left ventricular assist device patients?: how about bronze. | Q53292211 | ||
| Activation of endothelial and coagulation systems in left ventricular assist device recipients. | Q53370074 | ||
| Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation | Q84230319 | ||
| Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device | Q84498681 | ||
| Increased leukocyte-platelet interactions during circulatory support with left ventricular assist devices | Q84513605 | ||
| P433 | issue | 3 | |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 299-307 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Current Opinion in Cardiology | Q4626801 |
| P1476 | title | Bleeding and thrombosis in chronic ventricular assist device therapy: focus on platelets | |
| P478 | volume | 31 |
| Q98726641 | Comprehensive review of hemolysis in ventricular assist devices |
| Q98466848 | Post-operative of bleeding, haemolysis and coagulation in mechanical circulatory support patients |
| Q51092906 | Shear-mediated platelet activation in the free flow: Perspectives on the emerging spectrum of cell mechanobiological mechanisms mediating cardiovascular implant thrombosis. |
| Q38877999 | Short-term Results of Heartmate 3 Ventricular Assist Device Implantation for End-Stage Heart Failure |
Search more.